Glyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of obesity and Type 2 Diabetes.
Glyscend’s polymer technology platform evolved from research at Johns Hopkins University, and is designed to provide the benefits of bariatric surgery, without the need for an invasive surgery or procedure. Glyscend’s lead compound, GLY-200 is currently undergoing phase 2 studies.
